Mankind Pharma reported a 37.7% rise in quarterly net profit to Rs 711.5 crore, driven by a 33% surge in export formulations. However, the company's consumer healthcare business remained stagnant, leading analysts to maintain a cautious stance. Investors are now watching for a turnaround in the consumer segment against the backdrop of strong export performance.
Mankind Pharma reported strong financial results for the quarter ending September 2026, showing revenue growth of 17.3% compared to the same period last year. The company recorded total revenue of Rs 4,338 crore, which beat market projections. Net profit after tax rose by 37.7% to Rs 711.5 crore, supported by lower finance costs and a favorable effective tax rate. The company also achieved a profit margin of 16.4% for the quarter.
The primary growth driver for the quarter was the export formulations business, which expanded by 33% year-on-year. This performance provided a significant boost to the company's overall results. However, this growth was partially offset by the company's consumer healthcare segment, which remained stagnant throughout the period. The lack of movement in this division highlights the challenges the company faces in growing its non-prescription wellness business.
Management has indicated that it expects to continue outperforming the broader Indian Pharmaceutical Market, targeting a growth rate of 1.1 to 1.2 times the market average over the next two quarters. The company has reaffirmed its guidance for an EBITDA margin between 25.5% and 26.5% for the full fiscal year 2027. It continues to invest in research and development, allocating approximately 2.8% to 3.0% of its total revenue to these efforts.
Brokerage firm Systematix has maintained a 'Hold' rating on the stock with a target price of Rs 2,498. While analysts acknowledge the positive momentum in the export business, the stagnation in the consumer healthcare division remains a point of concern. The brokerage suggests that a meaningful recovery in the consumer healthcare segment may not materialize until fiscal year 2028.
For investors, the future trajectory will depend on the company's ability to balance its successful export strategy with a recovery in its domestic consumer healthcare products. Monitoring whether the company can improve its consumer segment performance in the coming quarters will be essential to understanding its long-term growth potential. The firm’s ability to sustain its margins while managing ongoing R&D spending also remains a critical factor for shareholders.